Oncology Molecular Diagnotics Medtech oncotech / EXIQON
Exclusive Advisor in Divestiture of Oncology Molecular Diagnostics Medtech Oncotech to Exiqon.
Exclusively advised the shareholders and Management of Oncotech of the US Molecular Diagnostics Company Oncotech to the Danish diagnostics company Exiqon for US$ 45m.
- January 21st, 2008: Final binding LOI with share for share exchange offer
- February 12th, 2008: Approval by a majority of Exiqon’s shareholders of the stock consideration
- February 2008: Issuance by Exiqon of 6,161,004 new shares to Oncotech as part of consideration
- February 29th, 2008: Closing of transaction.